

Potential methods to enhance prescribing efficiency, implications for sustaining healthcare systems

PPRI Conference, Austria 2011

B. Godman, Mohammed Abuelkhair B. Wettermark,
C. Berg, T. Burkhardt, C. Sermet, S. Sakshaug,
FC Tulunay, C. Zara



KAROLINSKA
INSTITUTET



هيئة الصحة - أبوظبي
HEALTH AUTHORITY - ABU DHABI



1 PPRI meeting

The majority of co-authors work for health authorities or health insurance agencies, or are advisers to them.

The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this presentation.

2 PPRI meeting

1. Introduction

2. Methodology

3. Impact of reforms among Western European countries

4. Care needed when planning

3. Conclusions and implications

3 PPRI meeting

European authorities have instigated a number of policies to enhance prescribing efficiency

- Focus of pharmaceutical expenditure will continue as:
 - ❑ The largest or equal largest component in ambulatory care, and growing the fastest
 - ❑ Continued launch of new premium priced medicines, changing demographics and rising patient expectation
 - ❑ Combined global sales of drugs of \$100bn/ year of drugs likely to lose their patent between 2008 and 2013
 - ❑ Cost of generics can vary up to 36 fold between countries and molecules/ strengths
 - ❑ Appreciable variation in utilisation patterns of generics between and within countries
- As a result, considerable opportunities for countries to learn from each other. This is resulting in a plethora of initiatives among countries as resource pressures grow

4 PPRI meeting

1. Introduction
- 2. Methodology**
3. Impact of reforms among Western European countries
4. Care needed when planning
5. Conclusions and implications

5 PPRI meeting

DDD and DDDs/ TID used to capture utilisation patterns. 4Es used to capture demand measures

- Retrospective analysis of the influence of demand side reforms on principally the utilisation of different PPIs (A02BC) in over 20 European countries/ regions and Abu Dhabi post generic availability (generic omeprazole)
- Only administrative databases used, with utilisation measured in DDDs and DDDs/ TID (ATC/DDD 2010)
- Demand side reforms broken down by 4Es (Education, engineering, economics and enforcement) and validated with payers in each country

6 PPRI meeting

Ref: Wettermark, Godman et al 2009; Godman, Shrank et al 2010; Godman, Shrank et al 2011

Main outcome measures centre on changes in utilisation patterns post generic availability

- Main outcome measures:
 - ❑ Changes in utilisation of omeprazole and esomeprazole as a % of all PPI utilisation just prior to the availability of generic omeprazole in each country and in 2007
 - ❑ Changes matched with demand side measures introduced (nature and intensity) to enhance prescribing of generics
- As a result, provide future direction to health authorities and health insurance agencies as they seek further savings


7 PPRI meeting

Ref: Godman, Shrank et al 2010; Godman, Shrank et al 2011

1. Introduction
2. Methodology
- 3. Impact of reforms among Western European countries**
4. Care needed when planning
5. Conclusions and implications

8 PPRI meeting


Intensity and nature of the reforms impacts on PPI utilisation patterns post generic omeprazole



9 PPRI meeting

Ref: Godman, Shrank et al 2010

Considerable differences in efficiency (PPIs) 2001 to 2007 across Europe with differences in reform intensity



10 PPRI meeting

Ref: Godman, Shrank et al 2011

**.. leading to differences in reimbursed expenditures
(Ireland over €60000 – but higher morbidity population)**



Country	Utilisation 2007 vs. 2001	Expenditure 2007 vs. 2001	€/1000 inhabitants in 2007
AT	↑ 3.6 fold	↑ 2.1 fold	€19299
DE	↑ 3.2 fold	↑ 1.4 fold	€13864
FR	↑ 2.1 fold	↑ 38%	€15194 (35% co-pays)
GB – Eng	↑ 2.3 fold	↓ 38%	€6186
IE	↑ 2.4 fold	↑ 2.6 fold	Over €60,000 (GMS population)
SE	↑ 42%	↓ 48%	€5832

11 PPRI meeting

Ref: Godman, Shrank et al 2010

1. Introduction
2. Methodology
3. Impact of reforms among Western European countries
- 4. Care needed when planning**
5. Conclusions and implications

12 PPRI meeting



HAAD has instigated a number of policies in recent years to enhance prescribing efficiency

- HAAD has instigated a range of measures to enhance the quality and efficiency of prescribing in recent years
- Policies include the development of a Unified Prescription Form (March 2009) and subsequent comprehensive Generic Drug Policy including compulsory INN prescribing (August 2009) apart from limited number of occasions
- However, pharmacists free to dispense originator or generic and be fully reimbursed, no reference pricing for the molecule and limited demand side measures directing physician prescribing

15 PPRI meeting

Utilisation and expenditure increased in all classes in HAAD in 2010 vs. 2009

- PPI utilisation increased by 10% with for instance single sourced esomeprazole increasing by 33% versus a reduction for multiple sourced omeprazole
- As a result, expenditure for the PPIs increased by 11% (2010 vs. 2009)
- Statin utilisation increased by 14% with atorvastatin/ rosuvastatin utilisation increasing by 14% (87.5% of total statins in 2010), utilisation of ezetimibe also increased
- Total expenditure on statins and ezetimibe increased by 11% (2010 vs. 2009)

16 PPRI meeting

1. Introduction
2. Methodology
3. Impact of reforms among Western European countries
4. Care needed when planning
- 5. Conclusions and implications**

17 PPRI meeting

Multiple intensive demand side measures influences efficiency. Care with enforcement

- Nature and intensity of demand side measures appreciably influences subsequent utilisation patterns post generic availability
- The intensity of demand side measures, coupled with the success of supply side measures to obtain low prices for generics, also considerably influences subsequent prescribing efficiency, e.g. PPIs
- Influence of measures appears additive – mirroring studies appraising the influence of measures to enhance guideline implementation
- Nature and follow-up of ‘Enforcement’ also important - else health authorities and health insurance agencies will fail to realise its full benefits

18 PPRI meeting

Thank You

Any Questions!

Brian.Godman@ki.se; godman@marionegri.it;
mail@briangodman.co.uk

19 PPR1 meeting